Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.41 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096679 | 0.89 | CTSK (0.51) | CTSKCTSLTAOK1TAOK3CASP1 | |
| SCHEMBL5096684 | 0.89 | CTSK (0.51) | CTSKCTSLTAOK1TAOK3CASP1 | |
| SCHEMBL6761955 | 0.84 | CTSK (0.52) | CTSKCTSLTAOK1TAOK3 | |
| SCHEMBL6771594 | 0.83 | CTSK (0.52) | CTSKCTSLKMT2A | |
| SCHEMBL6578042 | 0.80 | CTSK (0.54) | CTSKCTSLTAOK1TAOK3CASP1 | |
| SCHEMBL5099268 | 0.75 | CTSK (0.41) | CTSKCTSLTAOK1TAOK3CASP1 | |
| SCHEMBL6578118 | 0.74 | CTSK (0.51) | CTSKCTSLTAOK1TAOK3CASP1 | |
| SCHEMBL5092831 | 0.73 | CTSK (0.57) | CTSKCTSLKMT2A | |
| SCHEMBL6577927 | 0.73 | CASP1 (0.59) | CTSKCASP1CASP3CAPN1UTS2R | |
| SCHEMBL5099344 | 0.73 | CTSK (0.57) | CTSKCTSLTAOK1TAOK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885CTSL 25/4885TAOK1 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.